EVMN · Evommune, Inc.
$6.65
-0.27 (-3.90%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$308.12M
Shares
36.29M
Volume · Oct 5
1.37M
Avg daily vol (3M)
701.83K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.65
Open$6.86
Day$6.52–7.22
Available close range$6.65–31.57
Avg vol 30d788K
Short int2.9M · 7.9% float · 3.3d
Short vol32%
Last earningsMar 5, 2026
DataNov 2025–Oct 2026
Filing10-Q · Aug 6
The closing range uses available history since Nov 6, 2025; less than a full year is stored.
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$10.00M
Trailing 12 months
Net income (TTM)
−$94.67M
Trailing 12 months
Revenue growth YoY
+85.7%
Year over year
Operating margin
-1,018.9%
Trailing 12 months
P / E (TTM)
1.3
Trailing earnings · reciprocal yield 79.9%
FCF yield
-24.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$200.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,245.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.9%
Latest settlement · 3.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−65%
below
Price vs 50-day avg
−43%
below
RSI (14)
18
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−46%
trailing
6-month return
−75%
trailing
YTD return
−61%
this year
Relative strength
−87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $19 — 200d above 50d
Institutional flow
Accumulating
1 of 107 funds reported for Sep 30 · net +203 sh shares · +1 new
Insider flow
Accumulating
Net +$13.3K over 90 days · 0% sells
Short interest
Falling
7.93% of float · ▼ -34.1% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
107 holders — 13F breadth
Squeeze score
46
elevated · 0–100
Fundamentals
Revenue growth
+86%
Y/Y
EPS growth
+75%
Y/Y
Free cash flow
$-76.7M
Quant / Vol
risk profile
Volatility
121%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
10.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−65%
Bearish
Price vs 50-day avg
−43%
Bearish
RSI (14)
18
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $12 › 200d $19 — 200d above 50d
Institutional flow
Accumulating
1 of 107 funds reported for Sep 30 · net +203 sh shares · +1 new
Insider flow
Accumulating
Net +$13.3K over 90 days · 0% sells
Short interest
Falling
7.93% of float · ▼ -34.1% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
107 holders — 13F breadth
Price context
position in its available closing range
Range low $7
Now $7 · 0%
Range high $32
vs 200-day avg -65%
vs 50-day avg -43%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EVMN
this stock
Evommune, Inc.
|
$308.12M | -61.2% | +85.7% | — | 7.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EVMN | -20.7% | -45.8% | -75.0% | -19.5% | -61.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -21.9% | -46.4% | -86.6% | -21.1% | -74.8% |